MAPK8 and diffuse large B-cell lymphoma: JNK activation was previously observed in diffuse large-B-cell lymphoma (DLBCL) cells exposed to carfilzomib and HDACIs [33] and multiple myeloma cells exposed to bortezomib and NPI-0052 [45].